Navigation Links
'Corrective genes' closer thanks to enzyme modification
Date:7/28/2009

Scientists from the Universit de Montral and McGill University have re-engineered a human enzyme, a protein that accelerates chemical reactions within the human body, to become highly resistant to harmful agents such as chemotherapy, according to a new study published in The Journal of Biological Chemistry.

"Our team modified and decoded an enzyme structure," says Joelle Pelletier, a professor at the Universit de Montral's Department of Chemistry. "We discovered, to our surprise, that our intervention allowed the heart of the enzyme to increase its mobility. This unusual mobility caused the enzyme to resist the chemotherapy agent methotrexate a result we never predicted and one that offers promise."

The research team made its discovery as it sought ways to help correct genetic diseases. "Our goal is to improve the injection of corrective genes in people suffering from genetic diseases," say Pelletier who is also co-director of PROTEO, a Quebec-based research group on the function, structure and engineering of proteins. "This discovery will lead to promising new avenues."

"We were intrigued to find the enzyme's internal flexibility was impacted by our modifications and that this fact played such a crucial role for resistance," says Albert Berghuis, a professor at the McGill University Department of Biochemistry and Canada Research Chair in Structural Biology. "We can now harness this insight to further advance therapies for genetic diseases such as leukemia."


'/>"/>

Contact: Sophie Langlois
sophie.langlois@umontreal.ca
514-343-7704
University of Montreal
Source:Eurekalert

Page: 1

Related biology news :

1. Gene regulation, not just genes, is what sets humans apart
2. Interaction of just 2 genes governs coloration patterns in mice
3. Muscle mass: Scientists identify novel mode of transcriptional regulation during myogenesis
4. Study finds blocking angiogenesis signaling from inside cell may lead to serious health problems
5. Smoking turns on genes -- permanently
6. Genes, Environment and Health Initiative invests in genetic studies, environmental monitoring
7. Hebrew SeniorLife researchers search for aging, osteoporosis genes
8. UT Southwestern researchers identify hundreds of genes controlling female fertility
9. Genes and environment grant funds close look at nature-nurture overlap in common diseases
10. Jumping genes could make for safer gene delivery system
11. Genes from the father facilitate the formation of new species
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)...  Trovagene, Inc. (NASDAQ: TROV ), a ... that it has signed agreements with seven strategic partners ... Middle East for commercialization of the ... wave of international distribution agreements for Trovagene,s CLIA based ... The initial partners will introduce Trovagene,s liquid biopsy ...
(Date:1/11/2017)... -- Michael Johnson, co-founder of Visikol Inc. a company originally funded with ... to the elite "Forbes 30 Under 30" list in the Science ... 20 fields nationwide to be recognized as a leader in business ... ... a PhD candidate at Rutgers University. Visikol ...
(Date:1/4/2017)... thousands of attendees at this year,s International Consumer Electronics Show (CES), ... devices and services, will be featuring its new line of ULTRA CONNECT ... special CES Exhibit Suite , the new upper arm and wrist smart ... product platform.  Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:1/11/2017)... ... ... Back pain relief technology is now available without a prescription at What ... relief for WAR members. , This spinal restoration platform boasts utilization of technology that ... suffering from chronic back pain. , What A Relief Back Pain Centers ...
(Date:1/11/2017)... , PITTSBURGH and BENGALURU, ... (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, ... Drug Administration (FDA) has accepted Mylan,s biologics license application ... through the 351(k) pathway. This product is a proposed ... certain HER2-positive breast cancers. The anticipated FDA goal date ...
(Date:1/11/2017)... , Jan. 11, 2017  GenVec, Inc. ... delivery company, announced today that its chief scientific ... a talk entitled  "AdenoVerse™ platform for translational development ... Biotech Showcase at the upcoming Phacilitate Cell & ... Miami , Florida.  Dr. Brough,s presentation will ...
(Date:1/11/2017)... (PRWEB) , ... January 11, 2017 , ... ... signed a multi-year license agreement with Poseida Therapeutics Inc, the San Diego based ... genetic data. Poseida Therapeutics selected KBioBox in order to harness KBioBox’s powerful BioEngine ...
Breaking Biology Technology: